Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $113.90 | Total: $569.50 |
| 1 | 10 | $96.48 | Total: $964.80 |
| 1 | 25 | $81.74 | Total: $2,043.50 |
| 1 | 50 | $69.68 | Total: $3,484.00 |
| 1 | 100 | $60.30 | Total: $6,030.00 |
Overview
GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
Chemical Properties
| Molecular Formula | C24H30N6O2 |
| Molecular Weight | 434.53 |
| CAS Numbers | 2561414-56-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CCN1CCN(CC1)C(=O)Nc1cc(ccn1)-c1cn(C2CCOCC2)c2cnccc12 |
Storage and Handling
0C Short Term, -20C Long Term
References
Liu YA, et al. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes Discovery of 6-Azaindole Derivative GNF2133. J Med Chem. 2020 Mar 26;63[6] 2958-2973.